Silencing of IGHG1 reverses the resistance of pancreatic cancer to multidrug chemotherapy by modulating autophagy.
Sign Up to like & getrecommendations! Published in 2023 at "Environmental toxicology"
DOI: 10.1002/tox.23810
Abstract: BACKGROUND Pancreatic cancer is one of the most aggressive tumors with a high-mortality rate. First-line drugs include 5-fluorouracil (5-FU), gemcitabine (GEM), and oxaliplatin (OXA). Resistance to 5-FU, GEM, and OXA is a major challenge. Immunoglobulin… read more here.
Keywords: pancreatic cancer; gem oxa; resistance; silencing ighg1 ... See more keywords
Antitumour effects of a solid lipid nanoparticle loaded with gemcitabine and oxaliplatin on the viability, apoptosis, autophagy, and Hsp90 of ovarian cancer cells
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Microencapsulation"
DOI: 10.1080/02652048.2022.2109218
Abstract: Abstract The present study aimed to explore the sensitising capability of the anticancer agents, gemcitabine (GEM) and oxaliplatin (OXA), encapsulated in a novel SLN (GEM:OXA-SLN) against the ovarian cancer cell lines. A novel SLN, prepared… read more here.
Keywords: oxa sln; ovarian cancer; cancer; gem oxa ... See more keywords
DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53-deficient pancreatic cancer cells
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Medicine Reports"
DOI: 10.3892/mmr.2017.7923
Abstract: The aberrant expression of DNA methyltransferases (DNMTs) has been considered to be associated with pancreatic carcinogenesis and progression. DNMT3a is widely involved in cell proliferation and cell cycle progression in pancreatic ductal adenocarcinoma (PDAC) cells.… read more here.
Keywords: gem; chemosensitivity; chemosensitivity gemcitabine; p53 deficient ... See more keywords